E-mail: leona.reznickova@lfmotol.cuni.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Biology of Childhood Acute Hybrid Leukemias in a Population-Based Study (Czech Pediatric Hematology Working Group).
- Epigenetic Changes in CEBPα Gene and Xenotransplantation Model of B Cell Precursor Acute Lymphoblastic Leukemia Switching to Monocytoid Lineage During the Early Phase of the Treatment
- Epigenetic Status Of CEBPA Promoter and Expression Of CEBPα Correlates With Molecular Genetic Subtype and CD2 Aberrant Expression In B Cell Precursor ALL
- IMMUNOGLOBULIN AND T CELL RECEPTOR REARRANGEMENTS IDENTIFICATION REVEALS POTENTIALLY NEW SUBGROUP WITHIN PEDIATRIC ACUTE BIPHENOTYPIC LEUKEMIAS
- Limited Reliability of Ig/TCR Based MRD Monitoring in BCR/ABL-Positive Childhood ALL: Comparison to Quantitative Fusion Transcript Detection
- Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?
- MINIMAL RESIDUAL DISEASE ANALYSIS IN NON-MRD BASED TREATMENT PROTOCOL FOR CHILDHOOD ALL: LOW RISK FEATURES TOGETHER WITH FAST MORPHOLOGICAL RESPONSE FAIL TO IDENTIFY SLOW-RESPONDERS WITHIN THE ALL IC-BFM 2002 STANDARD RISK GROUP
- MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD AT DAY 15 PREDICTS PROGNOSIS OF CHILDHOOD B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA AND REFINES RISK STRATIFICATION BASED ON BONE MARROW
- MRD Monitoring Reveals a Specific Biology of BCR/ABL-Positive ALL
- PERIPHERAL BLOOD INVOLVEMENT PROVIDES AN IMPORTANT PROGNOSTIC INFORMATION DURING EARLY TIME POINTS OF CHILDHOOD ALL TREATMENT
- Prognostic Impact of Peripheral Blood Involvement during Early Time Points of Childhood ALL Treatment
- Přesmyk z lymfoidní do myeloidní linie během prednisonové předfáze u dětí léčených podle protokolu ALL IC BFM2002
